de Duve Institute at the Catholique University of Louvain

4 articles about de Duve Institute at the Catholique University of Louvain

• 

  Roche Focuses on T Regulatory Cells in $758 Million Acquisition of Tusk Thera...

  9/28/2018

  Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
• 

  AbbVie Exercises Option to Develop Argenx Immuno-Oncology Compound

  8/22/2018

  Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).

• arGEN-X and de Duve Institute at the Catholique University of Louvain to Collaborate on Novel Immunomodulation Therapy in Cancer

  11/4/2013

• Achilles Heel Of Common Childhood Tumor Identified, Harvard School of Dental Medicine, Harvard Medical School, and de Duve Institute at the Catholique University of Louvain Study

  10/20/2008